Transcaval versus Supra-Aortic Vascular Accesses for Transcatheter Aortic Valve Replacement : A Systematic Review with Meta-Analysis
A growing body of evidence suggests that extrathoracic vascular accesses for transcatheter aortic valve replacement (TAVR) yield favorable outcomes and can be considered as primary alternatives when the gold-standard transfemoral access is contraindicated. Data comparing the transcaval (TCv) to supra-aortic (SAo) approaches (transcarotid, transsubclavian, and transaxillary) for TAVR are lacking. We aimed to compare the outcomes and safety of TCv and SAo accesses for TAVR as alternatives to transfemoral TAVR. A systematic review with meta-analysis was performed by searching PubMed/MEDLINE and EMBASE databases for all articles comparing TCv-TAVR against SAo-TAVR published until September 2023. Outcomes included in-hospital or 30-day all-cause mortality (ACM) and postoperative complications. A total of three studies with 318 TCv-TAVR and 179 SAo-TAVR patients were included. No statistically significant difference was found regarding in-hospital or 30-day ACM (relative risk [RR] 1.04, 95% confidence interval [CI] 0.47-2.34, p = 0.91), major bleeding, the need for blood transfusions, major vascular complications, and acute kidney injury. TCv-TAVR was associated with a non-statistically significant lower rate of neurovascular complications (RR 0.39, 95%CI 0.14-1.09, p = 0.07). These results suggest that both approaches may be considered as first-line alternatives to transfemoral TAVR, depending on local expertise and patients' anatomy. Additional data from long-term cohort studies are needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 13(2024), 2 vom: 14. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Antiochos, Panagiotis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 28.01.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm13020455 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36747073X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36747073X | ||
| 003 | DE-627 | ||
| 005 | 20240128232040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm13020455 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1273.xml |
| 035 | |a (DE-627)NLM36747073X | ||
| 035 | |a (NLM)38256589 | ||
| 035 | |a (PII)455 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Antiochos, Panagiotis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transcaval versus Supra-Aortic Vascular Accesses for Transcatheter Aortic Valve Replacement |b A Systematic Review with Meta-Analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a A growing body of evidence suggests that extrathoracic vascular accesses for transcatheter aortic valve replacement (TAVR) yield favorable outcomes and can be considered as primary alternatives when the gold-standard transfemoral access is contraindicated. Data comparing the transcaval (TCv) to supra-aortic (SAo) approaches (transcarotid, transsubclavian, and transaxillary) for TAVR are lacking. We aimed to compare the outcomes and safety of TCv and SAo accesses for TAVR as alternatives to transfemoral TAVR. A systematic review with meta-analysis was performed by searching PubMed/MEDLINE and EMBASE databases for all articles comparing TCv-TAVR against SAo-TAVR published until September 2023. Outcomes included in-hospital or 30-day all-cause mortality (ACM) and postoperative complications. A total of three studies with 318 TCv-TAVR and 179 SAo-TAVR patients were included. No statistically significant difference was found regarding in-hospital or 30-day ACM (relative risk [RR] 1.04, 95% confidence interval [CI] 0.47-2.34, p = 0.91), major bleeding, the need for blood transfusions, major vascular complications, and acute kidney injury. TCv-TAVR was associated with a non-statistically significant lower rate of neurovascular complications (RR 0.39, 95%CI 0.14-1.09, p = 0.07). These results suggest that both approaches may be considered as first-line alternatives to transfemoral TAVR, depending on local expertise and patients' anatomy. Additional data from long-term cohort studies are needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a TAVI | |
| 650 | 4 | |a TAVR | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a supra-aortic | |
| 650 | 4 | |a transcatheter aortic valve replacement | |
| 650 | 4 | |a transcaval | |
| 700 | 1 | |a Kirsch, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Monney, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Tzimas, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Meier, David |e verfasserin |4 aut | |
| 700 | 1 | |a Fournier, Stephane |e verfasserin |4 aut | |
| 700 | 1 | |a Ferlay, Clémence |e verfasserin |4 aut | |
| 700 | 1 | |a Nowacka, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Rancati, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Abellan, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Skalidis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Muller, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Henri |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 13(2024), 2 vom: 14. Jan. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:2 |g day:14 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm13020455 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 2 |b 14 |c 01 | ||